Clinical Trials Logo
  1. Home
  2. Pyoderma Gangrenosum
  3. NCT01952275

Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases — NEUTROGENE  

Pyoderma Gangrenosum Clinical Trial

Official title:
Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses

Clinical Trial Summary

This study investigates the genetic architecture of Neutrophil-Mediated Inflammatory Skin Diseases. After collecting informed consent, all patients' clinical phenotype is graded at inclusion with a detailed case report form and a discovery cohort formed based on the certainty of diagnosis. The DNA of patients in the discovery cohort is analyzed by whole exome sequencing which identifies all protein-coding genetic variants. Subsequently, statistical burden tests are going to identify enrichment of rare coding genetic variants in patients affected by Neutrophil-Mediated Inflammatory Skin Diseases.

The ultimate goal is to reveal the responsible gene(s) that may then be targets for clinical intervention.

Clinical Trial Description

Timeframe:

- Collection of DNA for discovery cohort until 05/2016

- Data analysis until 12/2014 for pyoderma gangrenosum, until 12/2016 for other NMID

- Report and data presentation early 2015 for PG, 2017 for other NMID ;

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

  • Acute Generalized Exanthematous Pustulosis
  • Amicrobial Pustulosis of the Folds
  • Behcet Syndrome
  • Behcet's Disease
  • Bowel-associated Dermatosis-arthritis Syndrome
  • Bullous Systemic Lupus Erythematosus
  • Dermatitis
  • Dermatitis Herpetiformis
  • Epidermolysis Bullosa
  • Epidermolysis Bullosa Acquisita
  • Erosive Pustular Dermatosis of the Scalp
  • Erythema
  • Erythema Elevatum Diutinum
  • Erythema Marginatum
  • Familial Mediterranean Fever
  • Hidradenitis
  • IgA Pemphigus
  • Infantile Acropustulosis
  • Inflammatory Epidermolysis Bullosa Aquisita
  • Keratoderma Blenorrhagicum
  • Keratosis
  • Linear IgA Bullous Dermatosis
  • Lupus Erythematosus, Systemic
  • Medium Vessel Vasculitis
  • Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis)
  • Neutrophilic Eccrine Hidradenitis
  • Neutrophilic Urticaria
  • Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue
  • Pemphigus
  • Psoriasis
  • Pustular Psoriasis
  • Pyoderma
  • Pyoderma Gangrenosum
  • Rheumatoid Neutrophilic Dermatitis
  • Skin Diseases
  • Small Vessel Vasculitis Including Urticarial Vasculitis
  • Sneddon-Wilkinson Disease
  • Still's Disease
  • Sweet's Syndrome
  • Syndrome
  • Transient Neonatal Pustulosis
  • Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes
  • Urticaria
  • Vasculitis
Clinical Trial Details
NCT number NCT01952275
Study type Observational
Source University of Zurich
Contact Alexander Navarini, MD
Email alexander.navarini@usz.ch
Status Recruiting
Phase N/A
Start date January 2014
Completion date January 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06092216 - Spesolimab in Pyoderma Gangrenosum Phase 2
Completed NCT03311464 - A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan Phase 3
Recruiting NCT04901325 - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Phase 2
Completed NCT00791557 - Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease N/A
Terminated NCT02318914 - A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Phase 3
Terminated NCT02315417 - An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Phase 3
Completed NCT03137160 - An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT05984654 - Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum N/A
Completed NCT04895566 - Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma Early Phase 1
Withdrawn NCT04274166 - Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum Phase 2
Completed NCT01882504 - Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Withdrawn NCT00730717 - Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT03971643 - Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT04792957 - JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Not yet recruiting NCT05821374 - Deucravacitinib in PG Early Phase 1
Terminated NCT03072953 - Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Phase 2
Recruiting NCT05120726 - A Novel Therapeutic Treatment of Pyoderma Gangrenosum Phase 4
Withdrawn NCT00690846 - Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT01965613 - A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Phase 2
Completed NCT01302795 - Canakinumab for Pyoderma Gangrenosum Phase 2